Eledon Pharmaceuticals (NASDAQ:ELDN) completed enrollment of its phase 2 BESTOW trial using its immunosuppressive drug tegoprubart for the prevention of organ rejection in patients who undergo ...
For Eledon, the data adds to the potential indications for tegoprubart, which is pitching to enter a market for organ transplant immunosuppressant drugs that is expected to reach more than $6 ...
Keywords: pancreatic cancer, immunotherapy, molecular targets, tumour microenvironment, targeted drug Important Note: All contributions to this Research Topic must be within the scope of the section ...
Immunosuppressive drugs may cause electrocardiographic changes as increased QT interval (QTc) which is associated with a variety of cardiac diseases and sudden death. The aim of our study is to ...